Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has responded to the
company’s marketing authorization application (MAA) for
elbasvir/grazoprevir (50mg/100mg), which is under review for the
treatment of adult patients with chronic hepatitis C (HCV) infection.
Language:
English
Contact:
MerckMedia:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Hepatitis C Newsroom Research and Development News Corporate News Latest News #Merck #MRK $MRK elbasvir grazoprevir NYSE:MRK Source Type: news
More News: European Medicines Agency (EMA) | Hepatitis | Hepatitis C | Marketing | Merck | Pharmaceuticals